{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T02:54:20Z","timestamp":1786848860740,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biohaven Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to generate evidence to support psychometric validity of the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) among patients with spinocerebellar ataxia (SCA). Psychometric measurement properties and minimal change thresholds of the f-SARA were evaluated using data from a cohort of SCA subjects (recruited at Massachusetts General Hospital [MGH]; <jats:italic>n<\/jats:italic>\u2009=\u200933) and data from a phase 3 trial of troriluzole in adults with SCA (NCT03701399 [Study 206]; <jats:italic>n<\/jats:italic>\u2009=\u2009217), including a subset of patients with the SCA3 genotype (<jats:italic>n<\/jats:italic>\u2009=\u200989). f-SARA item ceiling effects were absent within the MGH cohort, while floor effects were present. Excellent internal consistency reliability was demonstrated (\u03b1<jats:sub>total<\/jats:sub>\u2009=\u20090.90; \u03b1<jats:sub>items-removed<\/jats:sub>\u2009=\u20090.86\u20130.90), and item-to-total correlations were strong (<jats:italic>r<\/jats:italic>\u2009=\u20090.82\u20130.91, per item). High test\u2013retest reliability was demonstrated with intraclass correlation coefficients of 0.91 (total) and 0.73\u20130.92 (items). Convergent and divergent validity was supported, with strong correlations observed between the f-SARA and similarly constructed scales (FARS-FUNC, BARS, PROM-ADL, and FARS-ADL; all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and weaker correlations observed among measures of differing constructs. Mean item and total scores increased with disease severity (by FARS-FUNC quartile; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). A 1-point threshold for meaningful changes was supported as 0.5\u2009\u00d7\u2009SD\u2009=\u20090.89, SEM\u2009=\u20091.12, and mean changes from baseline for patients classified as \u201cimproved,\u201d \u201cno change,\u201d or \u201cdeteriorated\u201d were\u2009\u22120.68, 0.02, and 0.58, respectively. Similar trends were observed in Study 206 all-SCA and SCA3 cohorts. The measurement properties of the f-SARA provide evidence of its psychometric validity, responsiveness, and suitability as a clinical outcome measure in patients with SCA, including those with SCA3.<\/jats:p>","DOI":"10.1007\/s12311-024-01707-9","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T10:02:07Z","timestamp":1718186527000},"page":"2095-2108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Psychometric Validation of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) in Patients With Spinocerebellar Ataxia"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-3354","authenticated-orcid":false,"given":"Michele","family":"Potashman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-3147","authenticated-orcid":false,"given":"Evan","family":"Popoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Wolfe","family":"Beiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-5125","authenticated-orcid":false,"given":"Jeremy","family":"Schmahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"1707_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","volume":"5","author":"T Klockgether","year":"2019","unstructured":"Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers. 2019;5:24. https:\/\/doi.org\/10.1038\/s41572-019-0074-3.","journal-title":"Nat Rev Dis Primers"},{"key":"1707_CR2","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00415-020-09815-2","volume":"268","author":"A Diallo","year":"2021","unstructured":"Diallo A, Jacobi H, Tezenas du Montcel S, Klockgether T. Natural history of most common spinocerebellar ataxia a: systematic review and meta-analysis. J Neurol. 2021;268:2749\u201356. https:\/\/doi.org\/10.1007\/s00415-020-09815-2.","journal-title":"J Neurol"},{"key":"1707_CR3","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s00415-021-10874-2","volume":"269","author":"KH Yap","year":"2022","unstructured":"Yap KH, Azmin S, Che Hamzah J, Ahmad N, van de Warrenburg B, Mohamed IN. Pharmacological and non-pharmacological management of spinocerebellar ataxia: a systematic review. J Neurol. 2022;269:2315\u201337. https:\/\/doi.org\/10.1007\/s00415-021-10874-2.","journal-title":"J Neurol"},{"key":"1707_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266:533\u201344. https:\/\/doi.org\/10.1007\/s00415-018-9076-4.","journal-title":"J Neurol"},{"key":"1707_CR5","unstructured":"Bhandari J, Thada PK, Samanta D. Spinocerebellar Ataxia, StatPearls. Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32491748. Accessed 1 Nov 2023."},{"key":"1707_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/mdc3.12822","volume":"6","author":"HAG Teive","year":"2019","unstructured":"Teive HAG, Meira AT, Camargo CHF, Munhoz RP. The geographic diversity of spinocerebellar ataxias (SCAs) in the Americas: a systematic review. Mov Disord Clin Pract. 2019;6:531\u201340. https:\/\/doi.org\/10.1002\/mdc3.12822.","journal-title":"Mov Disord Clin Pract"},{"key":"1707_CR7","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/mds.22288","volume":"23","author":"C Globas","year":"2008","unstructured":"Globas C, du Montcel ST, Baliko L, Boesch S, Depondt C, DiDonato S, Durr A, Filla A, Klockgether T, Mariotti C, Melegh B, Rakowicz M, Ribai P, Rola R, Schmitz-Hubsch T, Szymanski S, Timmann D, Van de Warrenburg BP, Bauer P, Schols L. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord. 2008;23:2232\u20138. https:\/\/doi.org\/10.1002\/mds.22288.","journal-title":"Mov Disord"},{"key":"1707_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s1474-4422(18)30042-5","volume":"17","author":"A Diallo","year":"2018","unstructured":"Diallo A, Jacobi H, Cook A, Labrum R, Durr A, Brice A, Charles P, Marelli C, Mariotti C, Nanetti L, Panzeri M, Rakowicz M, Sobanska A, Sulek A, Schmitz-H\u00fcbsch T, Sch\u00f6ls L, Hengel H, Melegh B, Filla A, Antenora A, Infante J, Berciano J, van de Warrenburg BP, Timmann D, Boesch S, Pandolfo M, Schulz JB, Bauer P, Giunti P, Kang JS, Klockgether T, Tezenas du Montcel S. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol. 2018;17:327\u201334. https:\/\/doi.org\/10.1016\/s1474-4422(18)30042-5.","journal-title":"Lancet Neurol"},{"key":"1707_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mds.22740","volume":"25","author":"T Schmitz-H\u00fcbsch","year":"2010","unstructured":"Schmitz-H\u00fcbsch T, Coudert M, Giunti P, Globas C, Baliko L, Fancellu R, Mariotti C, Filla A, Rakowicz M, Charles P, Ribai P, Szymanski S, Infante J, van de Warrenburg BPC, D\u00fcrr A, Timmann D, Boesch S, Rola R, Depondt C, Sch\u00f6ls L, Zdzienicka E, Kang J-S, Ratzka S, Kremer B, Schulz JB, Klopstock T, Melegh B, du Montcel ST, Klockgether T. Self-rated health status in spinocerebellar ataxia\u2014Results from a European multicenter study. Mov Disord. 2010;25:587\u201395. https:\/\/doi.org\/10.1002\/mds.22740.","journal-title":"Mov Disord"},{"key":"1707_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.nrl.2015.09.002","volume":"32","author":"CR Sanchez-Lopez","year":"2017","unstructured":"Sanchez-Lopez CR, Perestelo-Perez L, Escobar A, Lopez-Bastida J, Serrano-Aguilar P. Health-related quality of life in patients with spinocerebellar ataxia. Neurologia. 2017;32:143\u201351. https:\/\/doi.org\/10.1016\/j.nrl.2015.09.002.","journal-title":"Neurologia"},{"key":"1707_CR11","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","volume":"14","author":"T Ashizawa","year":"2018","unstructured":"Ashizawa T, \u00d6z G, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol. 2018;14:590\u2013605. https:\/\/doi.org\/10.1038\/s41582-018-0051-6.","journal-title":"Nat Rev Neurol"},{"key":"1707_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11940-019-0549-2","volume":"21","author":"CD Stephen","year":"2019","unstructured":"Stephen CD, Brizzi KT, Bouffard MA, Gomery P, Sullivan SL, Mello J, MacLean J, Schmahmann JD. The comprehensive management of cerebellar ataxia in adults. Curr Treat Options Neurol. 2019;21:9. https:\/\/doi.org\/10.1007\/s11940-019-0549-2.","journal-title":"Curr Treat Options Neurol"},{"key":"1707_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14737175.2022.2029703","volume":"22","author":"SD Ghanekar","year":"2022","unstructured":"Ghanekar SD, Kuo SH, Staffetti JS, Zesiewicz TA. Current and emerging treatment modalities for spinocerebellar ataxias. Expert Rev Neurother. 2022;22:101\u201314. https:\/\/doi.org\/10.1080\/14737175.2022.2029703.","journal-title":"Expert Rev Neurother"},{"key":"1707_CR14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/acn3.51370","volume":"8","author":"SM Brooker","year":"2021","unstructured":"Brooker SM, Edamakanti CR, Akasha SM, Kuo SH, Opal P. Spinocerebellar ataxia clinical trials: opportunities and challenges. Ann Clin Transl Neurol. 2021;8:1543\u201356. https:\/\/doi.org\/10.1002\/acn3.51370.","journal-title":"Ann Clin Transl Neurol"},{"key":"1707_CR15","doi-asserted-by":"publisher","first-page":"117417","DOI":"10.1016\/j.jns.2021.117417","volume":"424","author":"ML Chen","year":"2021","unstructured":"Chen ML, Lin CC, Rosenthal LS, Opal P, Kuo SH. Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development. J Neurol Sci. 2021;424:117417. https:\/\/doi.org\/10.1016\/j.jns.2021.117417.","journal-title":"J Neurol Sci"},{"key":"1707_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2021.08.014","volume":"91","author":"R Maas","year":"2021","unstructured":"Maas R, van de Warrenburg BPC. Exploring the clinical meaningfulness of the Scale for the Assessment and Rating of Ataxia: a comparison of patient and physician perspectives at the item level. Parkinsonism Relat Disord. 2021;91:37\u201341. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.08.014.","journal-title":"Parkinsonism Relat Disord"},{"key":"1707_CR17","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, Giunti P, Globas C, Infante J, Kang JS, Kremer B, Mariotti C, Melegh B, Pandolfo M, Rakowicz M, Ribai P, Rola R, Sch\u00f6ls L, Szymanski S, van de Warrenburg BP, D\u00fcrr A, Klockgether T, Fancellu R. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717\u201320. https:\/\/doi.org\/10.1212\/01.wnl.0000219042.60538.92.","journal-title":"Neurology"},{"key":"1707_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/mds.29255","volume":"38","author":"P Moulaire","year":"2023","unstructured":"Moulaire P, Poulet PE, Petit E, Klockgether T, Durr A, Ashisawa T, Tezenas du Montcel S. Temporal dynamics of the Scale for the Assessment and Rating of Ataxia in spinocerebellar ataxias. Mov Disord. 2023;38:35\u201344. https:\/\/doi.org\/10.1002\/mds.29255.","journal-title":"Mov Disord"},{"key":"1707_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/14737175.2017.1364628","volume":"17","author":"L Sarro","year":"2017","unstructured":"Sarro L, Nanetti L, Castaldo A, Mariotti C. Monitoring disease progression in spinocerebellar ataxias: implications for treatment and clinical research. Expert Rev Neurother. 2017;17:919\u201331. https:\/\/doi.org\/10.1080\/14737175.2017.1364628.","journal-title":"Expert Rev Neurother"},{"key":"1707_CR20","unstructured":"ClinicalTrials.gov. (NCT03701399) Troriluzole in Adult Subjects With Spinocerebellar Ataxia. https:\/\/classic.clinicaltrials.gov\/show\/NCT03701399. Accessed September 19 2023."},{"key":"1707_CR21","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1212\/WNL.96.15_supplement.2837","volume":"96","author":"M Beiner","year":"2021","unstructured":"Beiner M, Wirtz V, L\u2019Italien G, Ruggiero L, Berman R, Coric V. Analysis of 96 week, long-term open label extension phase of study BHV4157-201: a phase IIb\/III, randomized, double-blind, placebo-controlled trial of the safety and efficacy of troriluzole in adult subjects with spinocerebellar ataxia (2837). Neurology. 2021;96:2837.","journal-title":"Neurology"},{"key":"1707_CR22","unstructured":"US Food and Drug Administration. Patient-Focused Drug Development Guidance Public Workshop: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making. 2019, April. Available at: https:\/\/www.fda.gov\/media\/132505\/download?attachment. Accessed Nov 1 2023."},{"key":"1707_CR23","unstructured":"US Food and Drug Administration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2023, April. Available at: https:\/\/www.fda.gov\/media\/166830\/download. Accessed Nov 1 2023."},{"key":"1707_CR24","unstructured":"US Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. US Food and Drug Administration; 2009, December. Available at: https:\/\/www.fda.gov\/media\/77832\/download. Accessed Nov 1 2023."},{"key":"1707_CR25","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/mds.28670","volume":"36","author":"JD Schmahmann","year":"2021","unstructured":"Schmahmann JD, Pierce S, MacMore J, L\u2019Italien GJ. Development and validation of a patient-reported outcome measure of ataxia. Mov Disord. 2021;36:2367\u201377. https:\/\/doi.org\/10.1002\/mds.28670.","journal-title":"Mov Disord"},{"issue":"Pt 4","key":"1707_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/brain\/121.4.589","volume":"121","author":"T Klockgether","year":"1998","unstructured":"Klockgether T, Ludtke R, Kramer B, Abele M, Burk K, Schols L, Riess O, Laccone F, Boesch S, Lopes-Cendes I, Brice A, Inzelberg R, Zilber N, Dichgans J. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain. 1998;121(Pt 4):589\u2013600. https:\/\/doi.org\/10.1093\/brain\/121.4.589.","journal-title":"Brain"},{"key":"1707_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/bf01593882","volume":"4","author":"CA McHorney","year":"1995","unstructured":"McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995;4:293\u2013307. https:\/\/doi.org\/10.1007\/bf01593882.","journal-title":"Qual Life Res"},{"key":"1707_CR28","volume-title":"Psychometric theory","author":"JC Nunnally","year":"1994","unstructured":"Nunnally JC, Bernstein IH. Psychometric theory. New York: McGraw-Hill New York; 1994."},{"key":"1707_CR29","doi-asserted-by":"publisher","unstructured":"Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess. 1994;6:284\u201390. https:\/\/doi.org\/10.1037\/1040-3590.6.4.284","DOI":"10.1037\/1040-3590.6.4.284"},{"key":"1707_CR30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","volume":"64","author":"SH Subramony","year":"2005","unstructured":"Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, Taylor P, Wilson R, Ashizawa T. Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology. 2005;64:1261\u20132. https:\/\/doi.org\/10.1212\/01.WNL.0000156802.15466.79.","journal-title":"Neurology"},{"key":"1707_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","volume":"21","author":"RC Gershon","year":"2012","unstructured":"Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, Miller D, Peterman A, Cella D. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21:475\u201386. https:\/\/doi.org\/10.1007\/s11136-011-9958-8.","journal-title":"Qual Life Res"},{"key":"1707_CR32","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/mds.22681","volume":"24","author":"JD Schmahmann","year":"2009","unstructured":"Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov Disord. 2009;24:1820\u20138. https:\/\/doi.org\/10.1002\/mds.22681.","journal-title":"Mov Disord"},{"key":"1707_CR33","doi-asserted-by":"publisher","DOI":"10.1037\/t00742-000","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown G. Beck Depression Inventory\u2013II. PsycTESTS Dataset. 1996. https:\/\/doi.org\/10.1037\/t00742-000.","journal-title":"PsycTESTS Dataset"},{"key":"1707_CR34","doi-asserted-by":"publisher","unstructured":"Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893\u20137. https:\/\/doi.org\/10.1037\/\/0022-006x.56.6.893.","DOI":"10.1037\/\/0022-006x.56.6.893"},{"key":"1707_CR35","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"2013","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. Routledge; 2013."},{"key":"1707_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1179\/2042618612y.0000000001","volume":"20","author":"A Wright","year":"2012","unstructured":"Wright A, Hannon J, Hegedus EJ, Kavchak AE. Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther. 2012;20:160\u20136. https:\/\/doi.org\/10.1179\/2042618612y.0000000001.","journal-title":"J Man Manip Ther"},{"key":"1707_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1081\/copd-200050508","volume":"2","author":"NK Leidy","year":"2005","unstructured":"Leidy NK, Wyrwich KW. Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD. 2005;2:157\u201365. https:\/\/doi.org\/10.1081\/copd-200050508.","journal-title":"COPD"},{"key":"1707_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-4-70","volume":"4","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes. 2006;4:70. https:\/\/doi.org\/10.1186\/1477-7525-4-70.","journal-title":"Health Qual Life Outcomes"},{"key":"1707_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1207\/S15327752JPA8001_18","volume":"80","author":"DL Streiner","year":"2003","unstructured":"Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess. 2003;80:99\u2013103. https:\/\/doi.org\/10.1207\/S15327752JPA8001_18.","journal-title":"J Pers Assess."},{"key":"1707_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5116\/ijme.4dfb.8dfd","volume":"2","author":"M Tavakol","year":"2011","unstructured":"Tavakol M, Dennick R. Making sense of Cronbach\u2019s alpha. Int J Med Educ. 2011;2:53\u20135. https:\/\/doi.org\/10.5116\/ijme.4dfb.8dfd.","journal-title":"Int J Med Educ"},{"key":"1707_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jvs.2010.01.085","volume":"52","author":"FA Mazari","year":"2010","unstructured":"Mazari FA, Carradice D, Rahman MN, Khan JA, Mockford K, Mehta T, McCollum PT, Chetter IC. An analysis of relationship between quality of life indices and clinical improvement following intervention in patients with intermittent claudication due to femoropopliteal disease. J Vasc Surg. 2010;52:77\u201384. https:\/\/doi.org\/10.1016\/j.jvs.2010.01.085.","journal-title":"J Vasc Surg"},{"key":"1707_CR42","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/acr.20591","volume":"63","author":"M Hinchcliff","year":"2011","unstructured":"Hinchcliff M, Beaumont JL, Thavarajah K, Varga J, Chung A, Podlusky S, Carns M, Chang RW, Cella D. Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken). 2011;63:1620\u20138. https:\/\/doi.org\/10.1002\/acr.20591.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1707_CR43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12877-022-03527-0","volume":"23","author":"M Potashman","year":"2023","unstructured":"Potashman M, Pang M, Tahir M, Shahraz S, Dichter S, Perneczky R, Nolte S. Psychometric properties of the Alzheimer\u2019s Disease Cooperative Study-Activities of Daily Living for Mild Cognitive Impairment (ADCS-MCI-ADL) scale: a post hoc analysis of the ADCS ADC-008 trial. BMC Geriatr. 2023;23:124. https:\/\/doi.org\/10.1186\/s12877-022-03527-0.","journal-title":"BMC Geriatr"},{"key":"1707_CR44","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.26712","volume":"94","author":"A Trasch\u00fctz","year":"2023","unstructured":"Trasch\u00fctz A, Adarmes-G\u00f3mez AD, Anheim M, Baets J, Brais B, Gagnon C, Gburek-Augustat J, Doss S, Hana\u011fas\u0131 HA, Kamm C, Klivenyi P, Klockgether T, Klopstock T, Minnerop M, M\u00fcnchau A, Renaud M, Santorelli FM, Sch\u00f6ls L, Thieme A, Vielhaber S, van de Warrenburg BP, Zanni G, Hilgers RD, Synofzik M. Responsiveness of the Scale for the Assessment and Rating of Ataxia and natural history in 884 recessive and early onset ataxia patients. Ann Neurol. 2023;94:470\u201385. https:\/\/doi.org\/10.1002\/ana.26712.","journal-title":"Ann Neurol"},{"key":"1707_CR45","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/mds.29135","volume":"37","author":"R Maas","year":"2022","unstructured":"Maas R, Teerenstra S, Lima M, Pires P, Pereira de Almeida L, van Gaalen J, Timmann D, Infante J, Onyike C, Bushara K, Jacobi H, Reetz K, Santana MM, Afonso Ribeiro J, H\u00fcbener-Schmid J, de Vries JJ, Synofzik M, Sch\u00f6ls L, Garcia-Moreno H, Giunti P, Faber J, Klockgether T, van de Warrenburg BPC. Differential temporal dynamics of axial and appendicular ataxia in SCA3. Mov Disord. 2022;37:1850\u201360. https:\/\/doi.org\/10.1002\/mds.29135.","journal-title":"Mov Disord"},{"key":"1707_CR46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/practneurol-2018-002096","volume":"19","author":"RNd Silva","year":"2019","unstructured":"Silva RNd, Vallortigara J, Greenfield J, Hunt B, Giunti P, Hadjivassiliou M. Diagnosis and management of progressive ataxia in adults. Prac Neuro. 2019;19:196\u2013207. https:\/\/doi.org\/10.1136\/practneurol-2018-002096.","journal-title":"Prac Neuro"},{"key":"1707_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-024-01700-2","author":"M Potashman","year":"2024","unstructured":"Potashman M, Rudell K, Pavisic I, Suminski N, Doma R, Heinrich M, Abetz-Webb L, Beiner MW, Kuo SH, Rosenthal LS, Zesiwicz T, Fife TD, van de Warrenburg BP, Ristori G, Synofzik M, Perlman S, Schmahmann JD, L\u2019Italien G. Content validity of the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) instrument in spinocerebellar ataxia. Cerebellum. 2024. https:\/\/doi.org\/10.1007\/s12311-024-01700-2.","journal-title":"Cerebellum"},{"key":"1707_CR48","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s12311-022-01494-1","volume":"22","author":"MH Potashman","year":"2023","unstructured":"Potashman MH, Mize ML, Beiner MW, Pierce S, Coric V, Schmahmann JD. Ataxia rating scales reflect patient experience: an examination of the relationship between clinician assessments of cerebellar ataxia and patient-reported outcomes. Cerebellum. 2023;22:1257\u201373. https:\/\/doi.org\/10.1007\/s12311-022-01494-1.","journal-title":"Cerebellum"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-024-01707-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-024-01707-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-024-01707-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T02:13:59Z","timestamp":1729304039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12311-024-01707-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["1707"],"URL":"https:\/\/doi.org\/10.1007\/s12311-024-01707-9","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"27 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study 206 (BHV4157-206; NCT03701399) was a multisite study approved by a centralized independent Institutional Review Board (IRB; Advarra, Columbia, MD, USA) with additional local IRB approvals obtained where requested (per institute). The PROM-Ataxia study (MGH psychometric cohort) was approved by Mass General Brigham IRB (Somerville, MA, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients provided written consent to participate in the study and were free to withdraw at any time.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Michele Potashman, Ainsley Mackenzie, Melissa Wolfe Beiner, Vlad Coric, and Gilbert L\u2019Italien are employees of Biohaven Pharmaceuticals, Inc; Evan Popoff and Lauren Powell are employees of Broadstreet HEOR, which received funds from Biohaven Pharmaceuticals, Inc, for this work; Jeremy Schmahmann declares no conflict of interests. He consults for Biohaven Pharmaceuticals and is site PI for Biohaven Pharmaceuticals clinical trials NCT03701399, NCT02960893, and NCT03952806; receives royalties from Oxford University Press, Elsevier, MacKeith Press, and Springer; and is the inventor of the Brief Ataxia Rating Scale, Cerebellar Cognitive Affective\/Schmahmann Syndrome Scale, the Patient Reported Outcome Measure of Ataxia, and the Cerebellar Neuropsychiatry Rating Scale, which are licensed to the General Hospital Corporation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}